Cargando…

Engineering prostate cancer in vitro: what does it take?

A key challenge in the clinical management and cause of treatment failure of prostate cancer (PCa) is its molecular, cellular and clinical heterogeneity. Modelling systems that fully recapitulate clinical diversity and resistant phenotypes are urgently required for the development of successful pers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buskin, Adriana, Scott, Emma, Nelson, Ryan, Gaughan, Luke, Robson, Craig N., Heer, Rakesh, Hepburn, Anastasia C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403358/ https://www.ncbi.nlm.nih.gov/pubmed/37438470 http://dx.doi.org/10.1038/s41388-023-02776-6

Ejemplares similares

Engineering Prostate Cancer from Induced Pluripotent Stem Cells—New Opportunities to Develop Preclinical Tools in Prostate and Prostate Cancer Studies
por: Hepburn, Anastasia C., et al.
Publicado: (2020)

Propagation of human prostate tissue from induced pluripotent stem cells
por: Hepburn, Anastasia C., et al.
Publicado: (2020)

A Review of Prostate Organogenesis and a Role for iPSC-Derived Prostate Organoids to Study Prostate Development and Disease
por: Buskin, Adriana, et al.
Publicado: (2021)

Human prostate organoid generation and the identification of prostate development drivers using inductive rodent tissues
por: Singh, Parmveer, et al.
Publicado: (2023)

Human α(2)β(1) (HI) CD133(+VE) Epithelial Prostate Stem Cells Express Low Levels of Active Androgen Receptor
por: Williamson, Stuart C., et al.
Publicado: (2012)

A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities
por: Kounatidou, Evangelia, et al.
Publicado: (2019)

The co‐chaperone p23 promotes prostate cancer motility and metastasis
por: Querol Cano, Laia, et al.
Publicado: (2014)

Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer
por: Jones, Dominic, et al.
Publicado: (2017)

What does it take to get the job done?
por: Serpe, Mihaela
Publicado: (2015)

What Does It Take for Research to Be Rehabilitation Research?
por: Aadal, Lena, et al.
Publicado: (2022)

FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer
por: Jones, Dominic, et al.
Publicado: (2015)

The Integrated Care Workforce: What does it Need? Who does it Take?
por: Stein, K. V., et al.
Publicado: (2023)

Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer
por: Williamson, S C, et al.
Publicado: (2013)

Bridging the genotype–phenotype gap: what does it take?
por: Gjuvsland, Arne B, et al.
Publicado: (2013)

Side Population in Human Non-Muscle Invasive Bladder Cancer Enriches for Cancer Stem Cells That Are Maintained by MAPK Signalling
por: Hepburn, Anastasia C., et al.
Publicado: (2012)

Identification of CNGB1 as a Predictor of Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Hepburn, Anastasia C., et al.
Publicado: (2021)

A Novel Model of Urinary Tract Differentiation, Tissue Regeneration, and Disease: Reprogramming Human Prostate and Bladder Cells into Induced Pluripotent Stem Cells
por: Moad, Mohammad, et al.
Publicado: (2013)

The illusion of risk control: what does it take to live with uncertainty?
por: Motet, Gilles, et al.
Publicado: (2017)

What does it take to recruit and retain senior women faculty?
por: Watt, Fiona M
Publicado: (2013)

What does it take to be rigid? Reflections on the notion of rigidity in autism
por: Petrolini, Valentina, et al.
Publicado: (2023)

The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover
por: Coffey, Kelly, et al.
Publicado: (2013)

Strengthening health system leadership for better governance: what does it take?
por: Gilson, Lucy, et al.
Publicado: (2018)

Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer
por: McClurg, Urszula L., et al.
Publicado: (2015)

Deubiquitinating enzyme Usp12 regulates the interaction between the androgen receptor and the Akt pathway
por: McClurg, Urszula L., et al.
Publicado: (2014)

Targeting the DNA Double Strand Break Repair Machinery in Prostate Cancer
por: Shaheen, Fadhel S., et al.
Publicado: (2011)

Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation
por: Gaughan, Luke, et al.
Publicado: (2005)

Correction to ‘Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation’
por: Gaughan, Luke, et al.
Publicado: (2021)

What does it take to be healthy? Investigating immune-deficiency in non-immunodeficient scenarios
por: Binda, Elisa, et al.
Publicado: (2012)

What Does It Take for an Infant to Learn How to Use a Tool by Observation?
por: Fagard, Jacqueline, et al.
Publicado: (2016)

The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer
por: Adamson, Beth, et al.
Publicado: (2023)

Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells
por: Logan, Ian R., et al.
Publicado: (2016)

Developing a Competent Workforce for Integrated Health and Social Care: What Does It Take?
por: Stein, K Viktoria
Publicado: (2016)

What does it take to conduct clinical trials in African countries? Insights from Morocco
por: Benhima, Nada, et al.
Publicado: (2022)

Differential regulation of the androgen receptor by protein phosphatase regulatory subunits
por: Grey, James, et al.
Publicado: (2017)

Prostate-Specific Antigen fluctuation: what does it mean in diagnosis of prostate cancer?
por: Kim, Jun Seok, et al.
Publicado: (2015)

What will it take to increase breastfeeding?
por: Hernández‐Cordero, Sonia, et al.
Publicado: (2022)

Implementing CER: What Will It Take?
por: Biskupiak, Joseph E., et al.
Publicado: (2012)

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy
por: O'Neill, Daniel, et al.
Publicado: (2015)

What does it take to set goals for self-management in primary care? A qualitative study
por: Lenzen, Stephanie Anna, et al.
Publicado: (2016)

Editorial: What does it take to cure the brain? Studies toward genes, proteins, processes, and rehabilitation
por: Shu, Xinhua, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_67u7q2tgua1q2fpbjj4qpr9bgp